Preparations of artemisinin or its derivatives and amodiaquine or its derivatives and preparation method thereof

Abstract

The present invention discloses a preparation made up by using artemisinin or its derivative and amodiaquine or its derivative and its preparation method. Said preparation is formed from active component and pharmaceutically-acceptable solid additive, the described active component is the mixture formed from artemisinin or its derivative and amodiaquine or its derivative. Said preparation can high-effectively and durably kill plasmodia.

Description

technical field [0001] The invention relates to a compound preparation of artemisinin or its derivatives and amodiaquine for preventing and treating malaria and a preparation method thereof. Background technique [0002] Malaria is one of the most common diseases in the tropics and subtropics. At present, malaria is prevalent in nearly 100 countries around the world, and more than 2.5 billion people live in areas with high incidence of malaria. The number of malaria patients is 300 to 500 million people every year, and 2 to 3 million people are newly infected every year. 1 to 3 million people. What is more serious at present is that Plasmodium falciparum has developed resistance to commonly used antimalarial drugs through genetic mutation or adaptive ability, and has spread at a very high speed in various malaria regions around the world, especially in Southeast Asia. Although all countries are developing new antimalarial drugs for the prevention and treatment of drug-resi...

AI Technical Summary

Problems solved by technology

The disadvantage is that amodiaquine is more toxic than other antimalarial drugs. When the daily dose exceeds 52.8mg, it is prone to fatigue, dizziness, nausea, vomiting, abdominal pain, cyanosis, drug fever, etc., and a small number of red blood cells lack glucose 6-phosphate Patients with dehydrogenase can develop acute hemolytic anemia after medication, so WHO once prevented it